Through the joint venture, Leader Biomedical will further develop its eCOO tech platform, using supercritical CO2 to produce orthopedic, dental and wound-care tissue products, the company said.
“For more than a decade, I have been a firm believer in the potential of using supercritical CO2 to produce superior quality allografts. With this partnership we will improve patient care by delivering a safer, more efficient product and I am extremely glad to have Leader Biomedical on board,” BioTiss GmBH managing director Dr. Winkler said in a press release.
Leader Biomedical’s eCOO platform applies supercritical CO2 to produce safe osteogenic grafts, which the company claims is a “milder technique” compared to conventional tissue processing. The platform can be used to produce bone void fillers, structural grafts, demineralized bone matrixes, soft and connective tissues.
“I am excited to welcome Dr. Winkler as a valuable partner in this alliance, which is an important milestone in the global roll out of eCOO® Technology. It both expands Leader Biomedical’s allograft processing capacity in Europe and allows EMCM to focus on its core activities in the manufacturing of liquids, suspensions, and gels,” Leader Biomedical Group exec director Leo Liyeung said in prepared remarks.
As part of the partnership, Leader Biomedical said it will use BioTiss’ network of hospitals and tissue banks to market its products, including its newly acquired OSTEOmycin antibiotic-impregnated allografts.
“This alliance is more than just a consolidation of our manufacturing activities; it will set into motion a new wave of development and innovation, which will enable us to better serve our customers and patients alike,” Leader Biomedical biz director Basil Babychan said in a prepared statement.